Atea Pharmaceuticals
AVIR
AVIR
126 hedge funds and large institutions have $406M invested in Atea Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 37 increasing their positions, 42 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
126
Holders Change
–
Holders Change %
0%
% of All Funds
2.13%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.02%
New
22
Increased
37
Reduced
42
Closed
18
Calls
$14M
Puts
$935K
Net Calls
+$13M
Net Calls Change
+$14.4M
Top Buyers
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
$12.8M |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
$11.4M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
$25.5M |
| 4 |
BlackRock
New York
|
$52.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
$51M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
$1.84M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
$1.88M |
| 3 |
Renaissance Technologies
New York
|
$4.71M |
| 4 |
Two Sigma Investments
New York
|
$785K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
$164K |
